HSBC Sticks to Its Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)
HSBC analyst Linda Shu has reaffirmed a Buy rating for Hangzhou Tigermed Consulting Co., Ltd. Class H, setting a price target of HK$54.00. The stock closed at HK$44.04. Shu, a 3-star analyst, has an average return of 8.0% and a 64.71% success rate. The overall analyst consensus for the company is a Strong Buy, with an average price target of €5.92, indicating a potential downside of -86.56%. CLSA also maintains a Buy rating with a target of HK$52.10.
HSBC analyst Linda Shu maintained a Buy rating on Hangzhou Tigermed Consulting Co., Ltd. Class H on November 5 and set a price target of HK$54.00. The company’s shares closed last Wednesday at HK$44.04.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Shu is a 3-star analyst with an average return of 8.0% and a 64.71% success rate. Shu covers the Healthcare sector, focusing on stocks such as Pharmaron Beijing Co., Ltd. Class H, WuXi XDC Cayman, Inc., and WuXi AppTec Co., Ltd. Class H.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Hangzhou Tigermed Consulting Co., Ltd. Class H with a €5.92 average price target, implying a -86.56% downside from current levels. In a report released on October 30, CLSA also maintained a Buy rating on the stock with a HK$52.10 price target.
